Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus

Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Mar 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of etonogestrel implants on women with systemic lupus erythematosus (SLE), a condition that can affect the immune system and potentially impact fertility. The main goal is to find out if these implants can help protect the ovarian reserve function, which is the ability of the ovaries to produce eggs. Women aged 18 to 37 years with confirmed SLE may be eligible to participate. However, those with certain medical histories, such as hormonal disorders or recent hormone use, as well as those planning to become pregnant within the next year, will not be able to join.

In the trial, participants will be randomly assigned to either receive the etonogestrel implant or not receive any treatment for one year. After three months, researchers will compare the ovarian function between the two groups to see if the implant made a difference. This trial is important because it could provide valuable information on how to help women with SLE maintain their fertility options. Please note that the trial is not yet recruiting participants, so there will be some time before it begins.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Systemic lupus erythematosus was confirmed
• • 2. 18-37 years old
• Exclusion Criteria:
• • 1. History of sex chromosome abnormalities
• • 2. History of abnormal thyroid function
• • 3. History of abnormal adrenal function
• • 4. History of pituitary disease
• • 5. History of sexual hormone drug use in the past 3 months
• • 6. History of ovarian tumors or invasive ovarian operations
• • 7. Pregnancy
• • 8. Have a birth plan in the next 1 year
• • 9. Ovarian failure